cIMPACT-NOW Update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation

This cIMPACT-NOW update was published this month:Summary:cIMPACT (Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) has reviewed the status of WHO grade II IDH-wt/H3-wt diffuse gliomas, focusing on those with a BRAFV600E mutation, FGFR1 alteration, or a MYB or MYBL1 rearrangement, and recommends the use of an integrated diagnosis to combine their histologic and genetic features. The consortium ecommends the use of an integrated diagnosis to combine their histologic and genetic features, as suggested in the following:Diffuse glioma, MYB-alteredDiffuse glioma, MYBL1-alteredDiffuse glioma, FGFR1 TKD-duplicatedDiffuse glioma, FGFR1-mutantDiffuse glioma, BRAFV600E-mutant (but without CDKN2A/B deletion)Diffuse glioma, other MAPK pathway alterationThe full reference for cIMPACT Update 4 can be found at:Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G, Louis DN. cIMPACT-NOW update 4: diffuse gliomas characterized byMYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathol. https://doi.org/10.1007/s00401-019-01987-0.  PMID: 30848347Although our cIMPACT committee sees the utility of distinguishing these diffuse gliomas in diagnostic practice, it also acknowledges that the overlap between their morphologic and genetic features and those of other neuroepithelia...
Source: neuropathology blog - Category: Radiology Tags: molecular studies neoplasms Source Type: blogs